ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
The cash consideration for the acquisition is US$ 18 million.
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
Doctors can now analyse their historical prescriptions within a few clicks enabling them to identify different cohorts of patients and the treatment given to them
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
Subscribe To Our Newsletter & Stay Updated
